Galactosylated hydroxyl-polyamidoamine dendrimer targets hepatocytes and improves therapeutic outcomes in a severe model of acetaminophen poisoning-induced liver failure.

"data s1: supporting information click here for additional data file."

"CONFLICT OF INTEREST The authors (Rangaramanujam M. Kannan, Sujatha Kannan, Joshua E Porterfield, Rishi Sharma, and Anjali Sharma) have pending patents relating to the hepatocyte targeting and galactose‐dendrimer and PAMAM dendrimer platforms. Rangaramanujam M. Kannan and Sujatha Kannan are co‐founders of Ashvattha Therapeutics Inc., involved with the translation of dendrimer drug delivery platforms. Rangaramanujam M. Kannan and Sujatha Kannan serve as Board of Directors of Ashvattha Therapeutics Inc. till recently, and have financial interests which are managed by Johns Hopkins. Rishi Sharma worked at Ashvattha Therapeutics till recently. This work was done at Johns Hopkins before Rishi Sharma joined Ashvattha Therapeutics."

"Ambar Scarlet Jimenez was supported by the Johns Hopkins PREP grant (NIH R25GM109441). The authors also acknowledge the Wilmer core facility and imaging center (core grant: P30EY001765)."